ICOC Meeting Minutes May 15, 2020

Main Location:

CIRM Zoom

Other Locations:

All ICOC members participated via Zoom teleconference

	10 NP
	17 P
Doug Ziedonis (by phone)	NP
Keith Yamamoto	NP
Diane Winokur (by phone)	Р
Kristiina Vuori	NP
Art Torres	Р
Jonathan Thomas	Р
Oswald Steward (by phone)	Р
Jeff Sheehy	Р
Suzanne Sandmeyer	NP
Al Rowlett (by phone)	Р
Robert Quint (by phone)	Р
Francisco Prieto	Р
Joe Panetta (by phone)	Р
Adriana Padilla	Р
Lauren Miller	Р
Shlomo Melmed	Р
Dave Martin	Р
Linda Malkas	Р
Stephen Juelsgaard	Р
David Higgins	Р
Judy Gasson	NP
Ysabel Duron	NP
Anne-Marie Duliege	Р
Deborah Deas (by phone)	NP
Ken Burtis	NP
Linda Boxer (by phone)	NP
George Blumenthal	NP

OPEN SESSION:

ACTION ITEMS:

Agenda Item No. 4

Consideration of applications submitted in response to Clinical Trial Stage Projects for Sickle Cell Disease (CLIN 1 and 2.).

Presented by Gil Sambrano

Motion No. 1:

- Motion moved by David Higgins to fund Sickle Cell Disease project recommended by the GWG
- Motion seconded by Art Torres

Vote:

- The Application Review Subcommittee by unanimous vote approved the motion
- 12 YES; 0 NO; 0 ABSTENTIONS; 0 CONFLICTS

Agenda Item No. 3

Consideration of applications submitted in response to Special Call for COVID-19 Projects.

Presented by Gil Sambrano

Motion No. 2:

- Motion moved by Jonathan Thomas to move application 11823 from non-fundable range to fundable range.
- Motion seconded by Dave Martin

Vote:

- The Application Review Subcommittee by unanimous vote approved the motion
- 15 YES; 0 NO; 0 ABSTENTIONS; 0 CONFLICTS

Motion No. 3:

- Motion moved by Art Torres to approve all applications in Tier I, including application 11823 for funding.
- Motion seconded by Anne Marie Duliege

Vote:

• The Application Review Subcommittee approved the motion

• 14 YES; 1 NO; 0 ABSTENTIONS; 0 CONFLICTS

Motion No. 4:

- Motion moved by Anne Marie Duliege to not fund all remaining applications.
- Motion seconded by Os Steward

Vote:

- The Application Review Subcommittee by unanimous vote approved the motion
- 15 YES; 0 NO; 0 ABSTENTIONS; 0 CONFLICTS

DISCUSSION ITEMS:

Agenda Item No. 6

Public Comment

• There were no additional statements from the public.